500 集

In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.

OncLive® On Air OncLive® On Air

    • 健康與體能

In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.

    Miller Discusses the Use of Selinexor in TP53 Wild-Type Advanced Endometrial Cancer

    Miller Discusses the Use of Selinexor in TP53 Wild-Type Advanced Endometrial Cancer

    Dr Miller discusses findings from the SIENDO trial of selinexor maintenance therapy in patients with TP53 wild-type advanced endometrial cancer.

    • 11 分鐘
    Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer

    Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer

    Drs Park and Sonpavde discuss findings from the phase 1 DAD trial, as well as a schema for the frontline management of metastatic urothelial carcinoma. 

    • 22 分鐘
    Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa

    Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa

    Drs Bui and Kelly discuss key long-term findings from the AMPECT trial investigating nab-sirolimus in patients with advanced malignant PEComa.

    • 17 分鐘
    Curigliano on the DESTINY-Breast06 Trial in HER2-Low and -Ultralow Metastatic Breast Cancer

    Curigliano on the DESTINY-Breast06 Trial in HER2-Low and -Ultralow Metastatic Breast Cancer

    Dr Curigliano discusses the DESTINY-Breast06 trial of trastuzumab deruxtecan in patients with HER2-low or HER2-ultralow metastatic breast cancer.

    • 10 分鐘
    Orlowski on Isa-VRd in Transplant-Ineligible Multiple Myeloma

    Orlowski on Isa-VRd in Transplant-Ineligible Multiple Myeloma

    Dr Orlowski discusses key efficacy data from the IMROZ trial of Isa-VRd in newly diagnosed, transplant-ineligible multiple myeloma.

    • 10 分鐘
    Park and Sonpavde on Nivolumab Plus Gemcitabine/Cisplatin in Cisplatin-Eligible Urothelial Cancer

    Park and Sonpavde on Nivolumab Plus Gemcitabine/Cisplatin in Cisplatin-Eligible Urothelial Cancer

    Drs Park and Sonpavde discuss the CheckMate901 trial, which showed survival improvements with nivolumab plus chemotherapy in metastatic urothelial cancer.

    • 7 分鐘

關於健康與體能的熱門 Podcast

On Purpose with Jay Shetty
iHeartPodcasts
Vitamina P
Público
Clinical Conversations
NEJM Group
Intention to Treat
NEJM Group
The Lancet in conversation with
The Lancet Group
The Lancet Global Health in conversation with
The Lancet Group

你可能也會喜歡

Two Onc Docs
Sam and Karine
ASCO Daily News
American Society of Clinical Oncology (ASCO)
Oncology Today with Dr Neil Love
Research To Practice
Research To Practice | Oncology Videos
Dr Neil Love
NEJM AI Grand Rounds
NEJM Group
OncoPharm
John Bossaer